Opioid use, regulation, and harms in Brazil: a comprehensive narrative overview of available data and indicators

• Published in: Substance abuse treatment, prevention and policy prevention and policy, 2021-01, Vol.16 (1), p.12-10, Article 12
• Main Authors: Maia, Lucas O, Daldegan-Bueno, Dimitri, Fischer, Benedikt
• Format: Article
• Language: English
• Subjects: Analgesics; Complications and side effects; Dentists; Dosage and administration; Drug therapy; Fentanyl; Harms; Heroin; Laws, regulations and rules; Morbidity; Morphine; Mortality; Narcotics; Non‐medical use; Opioids; Pain; Policy; Population; Prescriptions; Public health; Review
• ISSN: 1747-597X; 1747-597X
• DOI: 10.1186/s13011-021-00348-z

Global opioid consumption increased multifold post-2000, disproportionately in high-income countries, with severe mortality/morbidity consequences. Latin America features comparatively low opioid availability; Brazil, the region's most populous country, makes an interesting case study concerning opioid use/harms. In this comprehensive overview, we aimed to identify and summarize medical and non-medical data and indicators of opioid availability and use, regulation/control, and harm outcomes in Brazil since 2000. We searched multiple scientific databases to identify relevant publications and conducted additional 'grey' literature searches to identify other pertinent information. Despite some essential indicators, opioid-related data are limited for Brazil. Data indicate that population-level availability of prescription opioids represents only a small fraction of use in comparison to high-income countries. However, within Latin America, Brazil ranks mid-level for opioid consumption, indicating relatively moderate consumption compared to neighboring jurisdictions. Brazil has implemented restrictive regulations to opioid prescribing and is considered 'highly restricted' for opioid access. Codeine remains the major opioid analgesic utilized, but stronger opioids such as oxycodone are becoming more common. Professional knowledge regarding medical opioid use and effects appears limited. National surveys indicate increases in non-medical use of prescription opioids, albeit lower than observed in North America, while illicit opioids (e.g., heroin) are highly uncommon. Overall population-level opioid availability and corresponding levels of opioid-related harms in Brazil remain substantially lower than rates reported for North America. However, the available surveillance and analytical data on opioid use, policy/practice, and harms in Brazil are limited and insufficient. Since existing and acute (e.g., pain-related) needs for improved opioid utilization and practice appear to be substantiated, improved indicators for and understanding of opioid use, practice, and harms in Brazil are required.